1 min read
Add as a preferred source on GoogleEU Panel Again Declines to Endorse Omeros Transplant Therapy
Omeros had also failed to secure the panel’s backing in an earlier review this year.
For a second time in 2026, an expert panel at the European Medicines Agency (EMA) declined to endorse narsoplimab, Omeros Corporation’s transplant therapy.
Omeros, a Seattle-based biotech, had also not secured the panel’s backing in an earlier review this year.
Riza Dagoc
Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.